Assoc. Prof. MD. Seher Nazlı Kazaz

Education and Training

• 1997–2005: Karadeniz Technical University, Faculty of Medicine – Medical Education

• 2007–2012: Karadeniz Technical University, Faculty of Medicine, Department of Internal Medicine – Doctorate/Specialization in Internal Medicine

• 2013–2017: Dokuz Eylul University, Faculty of Medicine, Division of Medical Oncology – Subspecialty in Medical Oncology

Memberships in Scientific Organizations

• Member, Trabzon Medical Chamber (since 2007)

• Member, Turkish Society of Medical Oncology (since 2014)

• Member, Oncology and Immunotherapy Association (since 2017)

A. Articles Published in International Peer-Reviewed Journals

• A1. Ulusoy S, Ozkan G, Sonmez M, Mungan S, Kaynar K, Cansiz M, Kazaz N. Absence of hypoalbuminemia despite nephrotic proteinuria in focal segmental glomerulosclerosis secondary to polycythemia vera. Internal Medicine (The Japanese Society of Medicine). 2010;49(22):2477-2480. DOI: 10.2169/internalmedicine.49.4087
• A2. Ulusoy S, Ozkan G, Bektaş D, Kaynar K, Cansız M, Kazaz N. Ramsay Hunt syndrome in a renal transplantation recipient: a case report. Transplantation Proceedings. 2010;42(5):1986-1988. DOI: 10.1016/j.transproceed.2010.02.078
• A3. Ozkan G, Ulusoy S, Kaynar K, Oztuna F, Cansiz M, Kazaz N. Swine H1N1 infection in a renal transplant recipient. Experimental and Clinical Transplantation. 2010;8(4):318-320. PMID: 21143099
• A4. Sonmez M, Kazaz N, Yucel B, Topbas M, Ucar F. C950T and C1181G osteoprotegerin gene polymorphisms in myeloma bone disease. Hematology. 2014;19(4):213-216. DOI: 10.1179/1607845413Y.0000000114
• A5. Salman T, Kazaz SN, Varol U, Oflazoglu U, Unek IT, Kucukzeybek Y, Alacacioglu A, Atag E, Semiz HS, Cengiz H, Oztop I, Tarhan MO. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for patients with neuroendocrine tumors: An Izmir Oncology Group study. Chemotherapy. 2016;61(6):281-286. DOI: 10.1159/000445045
• A6. Atag E, Kazaz SN, Semiz HS, Unek IT, Sarioglu S, Yavuzsen T. Epstein-Barr virus associated lymphoepithelioma-like carcinoma of the esophagogastric junction and stomach: A case report and review of the literature. Journal of Clinical and Experimental Oncology. 2016;5(6). DOI: 10.4172/2324-9110.1000171
• A7. Kurt S, Ulukus C, Kazaz SN, Astarcıoğlu I. Bilateral ovarian metastasis of a Klatskin tumor: A rare case. Turkish Journal of Obstetrics and Gynecology. 2016;13:215-217. DOI: 10.4274/tjod.40222
• A8. Kazaz SN, Oztop I. Treatment after crizotinib resistance in ALK+ non-small-cell lung cancer. International Journal of Hematology and Oncology. 2017;27(1). DOI: 10.4999/uhod.171786
• A9. Kazaz SN, Oztop I. Treatment after first-generation epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Turkish Thoracic Journal. 2017;18:66-71. DOI: 10.5152/TurkThoracJ.2017.16042
• A10. Kazaz SN, Oztop I. Immune checkpoint inhibitors in advanced-stage non-small-cell lung cancer. Turkish Thoracic Journal. 2017;18:101-107. DOI: 10.5152/TurkThoracJ.2017.17006
• A11. Buyruk AM, Kazaz SN, Oztop I, Semiz HS, Oflazoglu U, Somali I. The use of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and mean platelet volume (MPV) as inflammatory biomarkers in the prognosis of patients with early-stage colorectal adenocarcinoma. International Journal of Hematology and Oncology. 2017;27(4):220-228. DOI: 10.4999/uhod.171711
• A12. Atag E, Semiz HS, Kazaz SN, Tuna EB, Ozdogan O, Bozkurt O, Demir O, Karaoglu A. Response to cabazitaxel beyond 20 cycles in a patient with penile metastasis of prostate cancer: A case report. Urology Journal. 2017;14(1):2985-2988. DOI: 10.22037/uj.v14i1.3697
• A13. Eren H, Aydin HR, Tumkaya L, Kazaz IO, Kalkan Y, Kazaz SN, Mercantepe T, Horsanali MO, Yilmaz A. Whortleberry protects kidney against cisplatin-induced nephrotoxicity: An experimental study. Turkish Journal of Medical Sciences. 2018;40(1):466-474.
• A14. Yildirim S, Kazaz SN, Semiz HS, Yavuzsen T, Somalı I, Ellidokuz H, Oztop I. An evaluation of the information sources of cancer patients’ relatives: A prospective survey. Journal of Cancer Education. 2019;34:913-919. DOI: 10.1007/s13187-018-1384-5
• A15. Atag E, Mutlay F, Soysal P, Semiz HS, Kazaz SN, Keser M, Ellidokuz H, Karaoglu A. Prevalence of depressive symptoms in elderly cancer patients receiving chemotherapy and influencing factors. European Journal of Geriatrics and Gerontology. 2018;18(5):365-370.
• A16. Kazaz IO, Arslan A, Çolak F, Kazaz SN, Mungan S, Karagüzel E. Bladder metastasis of gastric signet-ring cell carcinoma. Urology Case Reports. 2019;22:62-62.
• A17. Kazaz IO, Ersoz S, Colak F, Teoman AS, Kazaz SN, Karaguzel E, Kutlu O. Primary renal angiosarcoma: A case report and a short review of the literature. Indian Journal of Pathology and Microbiology. 2020;63(5):44-46.
• A18. Semiz HS, Kazaz SN, Demir N, Güç ZG, Yavuzşen T, Ellidokuz H, Oztop I, Somalı I. Prognostic significance of hematological parameters in patients with early-stage malignant melanoma. UHOD – International Journal of Hematology and Oncology. 2020;30(2):103-109.
• A19. Kazaz IO, Özgür GK, Çobanoğlu Ü, Kalyoncu Nİ, Karagüzel E, Topbaş M, Eren H, Kazaz SN, Özyavuz R. Investigation of the effects of tadalafil and telmisartan in bleomycin-induced pulmonary fibrosis in rats. Journal of Surgery and Medicine. 2020;4(8):689-692.
• A20. Fidan E, Yildirim A, Kazaz N, Fidan S, Cekic AB. The relationship between albumin-bilirubin score and survival in patients operated for pancreatic cancer. Journal of Pakistan Medical Association. 2022;72(7):1340-1344. DOI: 10.47391/JPMA.2413
• A21. Kazaz SN, Yıldırım A. Evaluation of knowledge, attitudes and behaviours about COVID-19 among cancer patients. Annals of Clinical and Analytical Medicine. 2022;13(4):389-393.
• A22. Aynacı Ö, Serdar L, Rakıcı S, Kazaz S, Canyılmaz E, Bahat Z, Zengin AY. Radiotherapy in cancer treatment during the COVID-19 pandemic: One-year results from Northeast Turkey. Turkish Journal of Oncology. 2022;37(2):200-207. DOI: 10.5505/tjo.2022.3463
• A23. Dişli Ş, Fidan E, Özdover A, Kazaz N, Özdemir F. Complementary and alternative treatment use in breast cancer patients in the Eastern Black Sea region: A cross-sectional study. Indian Journal of Medical and Paediatric Oncology. 2022;43:270-277.
• A24. Fidan E, Fidan S, Merev E, Kazaz N. The relationship between albumin–bilirubin grade and survival in hepatocellular carcinoma patients treated with sorafenib. Nigerian Journal of Clinical Practice. 2022;25(2):173-177.

B. Authored International/National Books or Book Chapters

• B1. Textbook of Gastrointestinal Oncology (Editors: Suayib Yalcin, Philip A. Philip).
  Chapter: Symptom Management in Gastrointestinal Cancers.
  Authors: Tugba Yavuzsen, Nazli Kazaz, Özgür Tanriverdi, Tulay Akman, Meller P. Davis. (2019)

• B2. Radionuclide Therapy (Editors: Recep Bekiş, Berna Polack, Murat Fani Bozkurt).
  Chapter: Thyroid Diseases – Systemic Treatments and Side Effects in Thyroid Cancer.
  Authors: Seher Nazlı Kazaz, İlhan Öztop. (2019)

• B3. Radionuclide Therapy (Editors: Recep Bekiş, Berna Polack, Murat Fani Bozkurt).
  Chapter: Neuroendocrine Tumors – Systemic Treatments and Side Effects in Neuroendocrine Tumors.
  Authors: Seher Nazlı Kazaz, İlhan Öztop. (2019)

• B4. Türkiye Klinikleri Special Issue – Gynecological Cancers (Editor: Feyyaz Özdemir).
  Chapter: Systemic Treatment in Cervical Cancer.
  Authors: Seher Nazlı Kazaz, Fazıl Aydın. (2019)

• B5. Türkiye Klinikleri Special Topics – Medical Oncology: Lung Cancer (Editor: Ahmet Özet).
  Chapter: The Future of Lung Cancer.
  Authors: Seher Nazlı Kazaz, İlhan Öztop. (2020)

• B6. Türkiye Klinikleri Special Topics – Radiation Oncology: Multidisciplinary Treatment of Rectal Cancer (Editor: İlknur Birkay Görken).
  Chapter: Adjuvant Treatment in Rectal Cancer.
  Authors: Seher Nazlı Kazaz, İlhan Öztop. (2020)

• B7. Geriatric Oncology.
  Chapter: Scales in Geriatric Oncology.
  Authors: Seher Nazlı Kazaz, Tuğba Yavuzşen.

• B8. Geriatric Oncology.
  Chapter: Tyrosine Kinase Inhibitors in Geriatric Lung Cancer Patients.
  Authors: Seher Nazlı Kazaz, İlhan Öztop.

• B9. Türkiye Klinikleri – Ear, Nose and Throat – Special Topics: Oral Cavity Tumors.
  Chapter: Chemotherapy in Oral Cavity Cancers.
  Authors: Şafak Yıldırım Dişli, Seher Nazlı Kazaz, Feyyaz Özdemir.

• B10. TTOD – Breast Cancers.
  Chapter: Follow-Up and Prognosis in Hormone Receptor-Positive HER-2 Negative Breast Cancer.
  Authors: Seher Nazlı Kazaz, Evren Fidan.

• B11. Radionuclide Therapy (Editors: Recep Bekiş, Berna Polack, Murat Fani Bozkurt).
  Part II: Clinical Information: Thyroid Diseases.
  Chapter 8: Systemic Treatments and Related Side Effects in Thyroid Cancer.
  Authors: İlhan Öztop, Seher Nazlı Kazaz. Springer, 2022.

• B12. Radionuclide Therapy (Editors: Recep Bekiş, Berna Polack, Murat Fani Bozkurt).
  Part III: Clinical Information: Neuroendocrine Tumors.
  Chapter 10: Systemic Treatments and Related Side Effects in Neuroendocrine Tumors.
  Authors: İlhan Öztop, Seher Nazlı Kazaz. (2022)

C. Articles Published in National Peer-Reviewed Journals

• C1. Keser M, Kazaz SN, Karaoglu A. Medullary Thyroid Cancer. Türkiye Klinikleri Journal of Medical Oncology – Special Topics. 2017;10(1):91–96.

• C2. Semiz HS, Kazaz N, Karaoglu A. Adjuvant and Neoadjuvant Systemic Treatment in Lung Cancer. Türkiye Klinikleri Journal of Thoracic Surgery – Special Topics. 2017;8(1):264–271.

• C3. Alandag C, Kazaz SN, Cobanoglu B. Adenoid Cystic Carcinoma: A Single-Center 15-Year Experience. EJMI. 2021;5(4):491–495.

D. Papers Presented at International Scientific Meetings and Published in Proceedings

• D1. Sonmez M, Kazaz N, Yucel B, Topbas M, Ucar F. C950T and C1181G Osteoprotegerin Gene Polymorphisms in Myeloma Bone Disease. American Society of Hematology 55th Annual Meeting and Exposition, December 7–13, 2013, New Orleans, USA. Blood 2013;122:3128.

• D2. Yavuzsen T, Demir N, Oflazoglu U, Kazaz N, Somali I, Unek T, Sagol O, Sarioglu S, Atila K, Oztop I. HER2 Protein Over-Expression in Early Stage Gastric Cancer: Correlation with Clinicopathological Features and Survival. ESMO 17th World Congress on Gastrointestinal Cancer, July 1–4, 2015, Barcelona, Spain. Annals of Oncology 2015;26(suppl_4):iv26. DOI: 10.1093/annonc/mdv233.93

• D3. Unek IT, Kazaz SN, Semiz HS, Atag E, Oflazoglu U, Demir N, Baskin Y, Obuz F, Yavuzsen T, Somali I, Karaoglu A, Oztop I. Good Response to Panitumumab, Capecitabine and Oxaliplatin Combination (P-CapeOX) Regimen in a Patient with Liver Metastasis from Colon Cancer. 4th International Gastrointestinal Cancer Conference, December 12–14, 2014, Istanbul. (PS-031)

• D4. Semiz HS, Unek IT, Demir N, Atag E, Oflazoglu U, Kazaz SN, Somali I, Oztop I. Combination of Capecitabine and Vinorelbine for the Treatment of Synchronous Lung and Rectum Cancers: A Case Report. 4th International Gastrointestinal Cancer Conference, December 12–14, 2014, Istanbul. (PS-044)

• D5. Demir N, Unek IT, Oflazoglu U, Kazaz SN, Semiz HS, Atag E, Yavuzsen T, Somali I, Oztop I. Stomach Cancer in Adolescents and Young Adults: A Single Center Experience. 4th International Gastrointestinal Cancer Conference, December 12–14, 2014, Istanbul. (PS-066)

• D6. Kazaz SN, Unek IT, Demir N, Oflazoglu U, Atag E, Semiz HS, Unek T, Egeli T, Ozbilgin M, Astarcioglu IK, Oztop I. Pancreatic Ductal Adenocarcinoma in Young Adults: A Report of Four Cases. 4th International Gastrointestinal Cancer Conference, December 12–14, 2014, Istanbul. (PS-068)

• D7. Atag E, Unek IT, Demir N, Oflazoglu U, Kazaz SN, Semiz HS, Somali I, Karaoglu A, Bekis R, Oztop I. Synchronous Appearance of Gastric Carcinoma, Colon Carcinoma, and Renal Cell Carcinoma: A Case Report. 4th International Gastrointestinal Cancer Conference, December 12–14, 2014, Istanbul. (PS-071)

• D8. Atag E, Semiz HS, Kazaz SN, Demir N, Oflazoglu U, Unek IT, Yavuzsen T, Somali I, Karaoglu A. FOLFOXIRI and Bevacizumab Regimen as a Second-Line Therapy: A Case Report. 4th International Gastrointestinal Cancer Conference, December 12–14, 2014, Istanbul. (PS-083)

E. Papers Presented at National Scientific Meetings and Published in Proceedings

• E1. Gülsüm Özkan, Şükrü Ulusoy, Kübra Kaynar, Muammer Cansız, Funda Öztuna, Nazlı Kazaz. “Swine H1N1 Infection in a Renal Transplant Recipient.” 12th National Hypertension and Kidney Diseases Congress, May 19–23, 2010, Antalya, Congress Book, p005.

• E2. Gülsüm Özkan, Şükrü Ulusoy, Devrim Bektaş, Kübra Kaynar, Muammer Cansız, Nazlı Kazaz. “Ramsey-Hunt Syndrome in a Renal Transplant Recipient.” 12th National Hypertension and Kidney Diseases Congress, May 19–23, 2010, Antalya, Congress Book, p006.

• E3. Gülsüm Özkan, Şükrü Ulusoy, Mehmet Sönmez, Sevdegül Mungan, Kübra Kaynar, Muammer Cansız, Nazlı Kazaz. “Focal Segmental Glomerulosclerosis Secondary to Polycythemia Vera with Nephrotic Proteinuria and Normoalbuminemia.” 27th National Nephrology, Hypertension, Dialysis and Transplantation Congress, September 22–26, 2010, Antalya, Abstracts (PS/GN 086).

• E4. Seher Nazlı Kazaz, Rahman Köseoğlu, Esra Koç, Mehmet Sönmez. “Prognostic Impact of Early Decrease in Leukocyte Count with Chemotherapy in Patients with Acute Myeloid Leukemia.” 38th National Hematology Congress, October 31–November 3, 2012, Antalya, Abstract Book, pp.84–85 (P0153).

• E5. Elif Atağ, Necla Demir, Utku Oflazoğlu, Seher Nazlı Kazaz, Hüseyin Salih Semiz, Tuğba Yavuzşen, Işıl Somalı, İlhan Öztop, Aziz Karaoğlu. “Pathological and Clinical Features of Geriatric Breast Cancer Patients.” 1st Geriatric Oncology Congress & Molecular Nutrition in Geriatric Oncology Symposium, October 16–19, 2014, Antalya, Abstract Book, Breast Cancer-p0060.

• E6. Necla Demir, Utku Oflazoğlu, Seher Nazlı Kazaz, Hüseyin Salih Semiz, Elif Atağ, Tuğba Yavuzşen, İlhan Öztop. “Ipilimumab-Induced Autoimmune Hypophysitis: A Case Report.” 1st Geriatric Oncology Congress & Molecular Nutrition in Geriatric Oncology Symposium, October 16–19, 2014, Antalya, Abstract Book, Skin Cancer-p0004.

• E7. Nazlı Kazaz, Tuğba Yavuzşen, Aziz Karaoğlu, Işıl Somalı, Hülya Ellidokuz, İlhan Öztop. “Assessment of Frailty and Symptom Monitoring in Geriatric Oncology Patients Using the G-8 Questionnaire.” 1st Geriatric Oncology Congress & Molecular Nutrition in Geriatric Oncology Symposium, October 16–19, 2014, Antalya, Abstract Book, Geriatric Oncology Assessment-p0064.

• E8. Utku Oflazoğlu, Necla Demir, İlhan Öztop, Işıl Somalı, Seher Nazlı Kazaz, Tuğba Yavuzşen, Aziz Karaoğlu. “ALK Rearrangement Results and Clinicopathological Demographic Characteristics: A Single-Center Study.” 10th National Oncological Research Workshop, November 6–9, 2014, Antalya (pp.11–12).

• E9. Seher Nazlı Kazaz, Elif Atağ, Hüseyin Salih Semiz, Utku Oflazoğlu, Necla Demir, Hatice Binnaz Miraç Demirkan, İlkay Tuğba Ünek, Tuğba Yavuzşen, Işıl Somalı, Aziz Karaoğlu, Sülen Sarıoğlu, Özgür Sağol, Funda Obuz, Selman Sökmen, İlhan Öztop. “Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Colon: A Rare and Rapidly Progressive Case.” 2nd Rare Tumors Symposium, February 27–March 1, 2015, İzmir (pp.7–8).

• E10. Tarık Salman, Nazlı Apaydın, İbrahim Yıldız, Utku Oflazoğlu, Necla Demir, Umut Varol, Ahmet Alacacıoğlu, İlhan Öztop, Hakan Cengiz. “Tubular Gastrointestinal Neuroendocrine Tumors: A Two-Center Study.” 2nd Rare Tumors Symposium, February 27–March 1, 2015, İzmir (p.12).

• E11–E33. Various case reports and research presentations on rare tumors, geriatric oncology, lung and colorectal cancers, and chemotherapy outcomes presented at the 21st National Cancer Congress (2015), 2nd Geriatric Oncology Congress (2016), 5th Oncology Research Symposium (2016), and 7th National Lung Cancer Congress (2016) in Antalya and İzmir.

• E34. Semiz H.S., Kazaz S.N., Öztop İ. “Excellent Survival in Metastatic Malignant Melanoma: A Case Report.” 3rd National Immuno-Oncology and Targeted Cancer Therapy Congress, May 11–15, 2016, Antalya (p-33).

• E35. Elif Atağ, Seher Nazlı Kazaz, Hüseyin Salih Semiz, Ayça Ersen, İlkay Tuğba Ünek, İlhan Öztop. “Pulmonary Blastoma: A Rare Lung Tumor in a Young Patient.” 4th Rare Tumors Symposium, February 24–26, 2017, İzmir (pp.21–22).

• E36. Şafak Yıldırım Dişli, Seher Nazlı Kazaz. “Abiraterone Acetate and Enzalutamide in Geriatric Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Experience.” 4th Geriatric Oncology Congress (Online), December 12–13, 2020 (Oral Presentation).

• E37. Seher Nazlı Kazaz. “Evaluation of Efficacy and Adverse Effects of Immunotherapy in Geriatric Cancer Patients: A Single-Center Experience.” 4th Geriatric Oncology Congress (Online), December 12–13, 2020 (Oral Presentation).

• E38. Atilla Yıldırım, Seher Nazlı Kazaz. “Metastatic Lung Adenocarcinoma with Concurrent EGFR Mutation and ALK Rearrangement: A Case Report.” 4th Young Perspectives in Oncology Congress (Oral Presentation).

F. Other

I. Congresses, Symposiums, and Meetings Attended as a Speaker

• FI1. Seher Nazlı Kazaz, “İmmunoterapide Yan Etki Yönetimi – Kardiyak Yan Etkileri ve Yönetimi,” 5th Symposium on Pursuits in Oncology, November 4–6, 2016, İzmir (Speaker).

• FI2. Seher Nazlı Kazaz, “Akciğer Kanseri 2 – Akciğer Adenoca Çok Basamak Kemoterapi Almış Hastada İmmunoterapi ve Yan Etki Yönetimi,” 1st National Oncology with Clinical Cases Congress of the Immuno-Oncology Association, December 15–17, 2016, Antalya (Speaker).

• FI3. Seher Nazlı Kazaz, “Akciğer Kanserinde Hedefe Yönelik ve İmmunoonkolojik Tedaviler – ROS, MEK ve Diğer Hedefli Tedaviler,” 4th Black Sea Oncology Symposium, September 29–October 1, 2017, Trabzon (Speaker).

• FI4. Seher Nazlı Kazaz, “Moleküler Temelli Tedavilerde Yan Etki Yönetimi – Tirozin Kinaz İnhibitör Tedavilerinde Yan Etki Yönetimi,” 6th Symposium on Pursuits in Oncology, November 10–12, 2017, İzmir (Speaker).

• FI5. Seher Nazlı Kazaz, “Akılcı İlaç Kullanımı,” 2nd Eskişehir Oncology Days, April 5–7, 2019, Eskişehir (Speaker).

• FI6. Seher Nazlı Kazaz, “Perioperatif Kemoterapi: Neoadjuvan–Adjuvan,” Eurasian Urooncology Association Multidisciplinary Urooncology Meeting, May 3, 2019, Trabzon (Speaker).

• FI7. Seher Nazlı Kazaz, “Perioperatif Sistemik İmmunoterapi: Nereye Gidiyoruz?”, Eurasian Urooncology Association Multidisciplinary Urooncology Meeting, May 3, 2019, Trabzon (Speaker).

• FI8. Seher Nazlı Kazaz, “İmmunoterapilerde Yan Etki Yönetimi,” Postgraduate Update Course of the Turkish Society of Medical Oncology – Basic Oncology Training Course, October 6, 2019, Trabzon (Speaker).

• FI9. Seher Nazlı Kazaz, “Metastatik Malign Melanomda İmmunoterapi,” 6th Black Sea Oncology Symposium, September 19–22, 2019, Trabzon (Speaker).

• FI10. Seher Nazlı Kazaz, “KHDAK’nin Moleküler Temelli Tedavisinde Medikal Onkoloğun Temel Onkologdan Beklentileri ve Potansiyel Araştırma Alanları,” 8th Symposium on Pursuits in Oncology, December 13–15, 2019, İzmir (Speaker).

• FI11. Seher Nazlı Kazaz, “Meme Kanserinde Neoadjuvan Tedavi: Kime?”, 4th Black Sea Surgical Days – Breast Diseases, February 8, 2020, Rize (Speaker).

• FI12. Seher Nazlı Kazaz, “Sözel Bildiriler,” From AACR to ASCO: Updates in Oncology Practice, e-Congress, June 13–14, 2020 (Session Chair).

• FI13. Seher Nazlı Kazaz, “Kongreden Akılda Kalanlar,” 4th Geriatric Oncology Congress, e-Congress, December 12–13, 2020 (Speaker).

• FI14. Seher Nazlı Kazaz, “mKRK’inde İdeal Tedavi için Sıralama Nasıl Olmalı?”, Amgen-Satellite, 4th Young Perspectives in Oncology Congress, February 12–14, 2021 (Speaker).

• FI15. Seher Nazlı Kazaz, Head and Neck Cancer Association Multidisciplinary Tumor Board – Case Presentation, e-Meeting (Speaker).

• FI16. Seher Nazlı Kazaz, “Prostat Kanserinde Hormon Tedavisinde Yenilikler,” 5th Course on Immuno-Oncological and Molecular Oncological Treatments in Cancer, October 1–3, 2021, e-Meeting (Speaker).

• FI17. Seher Nazlı Kazaz, “Multidisipliner Tümör Konseyi: Akciğer Kanserleri,” 8th TTOK 2021, November 3–7, 2021 (Speaker).

• FI18. Seher Nazlı Kazaz, “KHDAK’de Biyobelirteçlerin Takip ve Tedavideki Yeri,” 9th Symposium on Pursuits in Oncology 2021, November 12–13, 2021, e-Meeting (Speaker).

• FI19. Seher Nazlı Kazaz, “Olgularla Akciğer Kanserinde Hedefli Tedaviler,” TAKD–Marmara and Black Sea Joint Meeting, January 12, 2022, e-Meeting (Speaker).

• FI20. Seher Nazlı Kazaz, “Metastatik KHDAK’nde Nadir Mutasyonlarda Güncel Yaklaşım,” 3rd Eskişehir Oncology Days, March 11–13, 2022 (Speaker).

• FI21. Seher Nazlı Kazaz, “Ürogenital Kanserlerde Yeni Tedaviler, Prostat Kanseri,” 7th Black Sea Oncology Days, March 24–26, 2022 (Speaker).

• FI22. Seher Nazlı Kazaz, “Multidisipliner Tümör Konseyi: Non-Tubuler GIS Tümörleri,” 9th TTOK 2021, May 18–22, 2022 (Speaker).

• FI23. Seher Nazlı Kazaz, “Debate: Özefagogastrik Bileşke Tümörlerinde Neoadjuvan KT vs KRT – Neoadjuvan KT,” 6th National Immunotherapy and Oncology Congress, October 19–23, 2022 (Mentor).

II. Course Participation

• FII1. Karadeniz Technical University Faculty of Medicine, “Rational Drug Selection and Use (Rational Pharmacotherapy) Course,” December 21–24, 2004, Trabzon.

• FII2. Karadeniz Technical University Faculty of Medicine, “Kidney Transplant Pathology Course,” March 22, 2009, Trabzon.

• FII3. Turkish Society of Medical Oncology, Postgraduate Update Course “Head and Neck & CNS Cancers Course,” January 11–12, 2014, Istanbul.

• FII4. Turkish Society of Medical Oncology Regional Course “Thoracic Oncology Western Region Course,” February 15, 2014, Denizli.

• FII5. Turkish Society of Medical Oncology Postgraduate Update Course “Sarcomas and Dermatological Cancers Course,” October 11–12, 2014, Istanbul.

• FII6. Dokuz Eylül University Faculty of Medicine, “Pharmacovigilance and Adverse Reaction Reporting Training,” June 19, 2015, İzmir.

• FII7. Immuno-Oncology Association, 2nd Immuno-Oncology and Targeted Cancer Therapies Congress, “Malignant Melanoma Course,” May 13, 2015, Antalya.

• FII8. Klinikum Oldenburg Oncological Center, “Educational Course on Diagnosis, Treatment, and Multidisciplinary Management of Metastatic Colorectal Cancer,” November 11–12, 2015, Oldenburg, Germany.

• FII9. Turkish Society of Medical Oncology Postgraduate Update Course “Basic Oncology Training Course,” April 1–2, 2017, İzmir.

• FII10. Turkish Society of Medical Oncology Postgraduate Update Course “Basic Oncology Training Course,” October 6, 2019, Trabzon (Speaker).

• FII11. Karadeniz Technical University Clinical Research Center (KTÜKAM), “Good Clinical Practices (GCP) Course,” May 17–18, 2019, Trabzon (Certificate).

• FII12. 5th Course on Immuno-Oncological and Molecular Oncological Treatments in Cancer, “Prostat Kanserinde Hormon Tedavisinde Yenilikler,” October 1–3, 2021, e-Meeting (Speaker).

III. Congress Participation

• FIII1. 1st National Gastrointestinal Oncology Congress, April 3–5, 2009, Antalya

• FIII2. 1st Symposium on Targeted Therapies in Cancer, June 17–19, 2011, Trabzon

• FIII3. 9th European International Kidney Cancer Symposium (EIKCS), April 25–26, 2014, Dublin, Ireland

• FIII4. Turkish Society of Medical Oncology – Best of ASCO 2014 Annual Meeting, June 21–22, 2014, Istanbul

• FIII5. İzmir Oncology Group – 1st Rare Tumors Symposium, February 28–March 2, 2014, İzmir

• FIII6. İzmir Oncology Group – 2nd Rare Tumors Symposium, February 27–March 1, 2015, İzmir

• FIII7. 21st National Cancer Congress, April 22–26, 2015, Antalya

• FIII8. 2nd Immuno-Oncology and Targeted Cancer Therapies Congress, May 13–17, 2015, Antalya

• FIII9. 2nd Geriatric Oncology Congress, October 20–23, 2016, Antalya

• FIII10. 7th National Lung Cancer Congress, November 24–27, 2016, Antalya

• FIII11. 25th Year Symposium on Multidisciplinary Approach to Cancer – Dokuz Eylül Experience, November 11–12, 2016, İzmir

• FIII12. 5th Symposium on Advances in Oncology, November 4–6, 2016, İzmir

• FIII13. 15th St. Gallen International Breast Cancer Conference 2017, March 15–18, 2017, Vienna, Austria

• FIII14. 3rd Geriatric Oncology Congress, November 9–11, 2018, Antalya

• FIII15. 23rd National Cancer Congress, April 17–21, 2019, Antalya

• FIII16. ESMO 2019, September 27–October 1, 2019, Barcelona, Spain

• FIII17. EMUC 2019 – 11th European Multidisciplinary Congress on Urological Cancers, November 14–17, 2019, Vienna, Austria

• FIII18. ASCO 2020 – New Developments and Updates, TTOD Sessions, June 1–5, 2020, e-Congress

• FIII19. 4th National Immunotherapy and Oncology Congress, October 29–November 1, 2020, “Oral Presentations,” e-Congress (Session Chair)

• FIII20. ESMO 2020, e-Congress

• FIII21. ASCO 2020, e-Congress

• FIII22. TAKD 2021, e-Congress

• FIII23. ASCO 2021, e-Congress

• FIII24. 10th World Melanoma Congress, 2021, e-Congress

• FIII25. 5th National Immunotherapy and Oncology Congress, October 13–17, 2021, “Oral Presentations – Head and Neck and Others,” e-Congress (Session Chair)

• FIII26. 8th TTOK Congress

• FIII27. 9th Symposium on Advances in Oncology

• FIII28. 3rd Eskişehir Oncology Days

• FIII29. 7th Black Sea Oncology Days

• FIII30. 9th TTOK Congress

• FIII31. 6th National Immunotherapy and Oncology Congress, October 19–23, 2022

IV. Participation in Good Clinical Practice and Clinical Research

• PERTAIN (NCT01491737) — Investigator

• PERUSE (NCT01572038) — Investigator

• HERiTAge Protocol MYL-HER-3001 (NCT02472964) — Investigator (terminated before initiation in Türkiye)

• ASQoP (NCT01571284) — Investigator

• ExteNET (NCT00878709) — Investigator

• D-CARE (NCT01077154) — Investigator

• Javelin Lung 200 (NCT02395172) — Investigator

• MK-3475-KEYNOTE-905 (NCT03924895) — Investigator

• MK-3475-KEYNOTE-866 (NCT03924856) — Investigator

• Tislelizumab (BGB-A317) + Chemotherapy (NCT03777657) — Principal Investigator

• MK-3475-KEYNOTE-992 (NCT04241185) — Principal Investigator

• BLC 2002 NORSE (NCT03473743) — Principal Investigator

• CBYL719K12301 — Principal Investigator

Citations: Total of 156 citations (h-index: 7, i-10 index: 5)

Selected Publications Cited:

• Response to Cabazitaxel Beyond 20 Cycles in a Patient with Penile Metastasis of Prostate Cancer: A Case Report
  Atag E, Semiz HS, Kazaz SN, Tuna EB, Ozdogan O, Bozkurt O, Demir O, Karaoglu A.
  Urology Journal, 14(1): 2985–2988, Jan-Feb 2017.
  Total Citations: 1

• Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Patients with Neuroendocrine Tumors: An Izmir Oncology Group Study
  Salman T, Kazaz SN, Varol U, Oflazoglu U, Unek IT, Kucukzeybek Y, Alacacioglu A, Atag E, Semiz HS, Cengiz H, et al.
  Chemotherapy, 61(6): 281–286, 2015. DOI: 10.1159/000445045
  Total Citations: 7

• C950T and C1181G Osteoprotegerin Gene Polymorphisms in Myeloma Bone Disease
  Sonmez M, Kazaz N, Yucel B, Topbas M, Ucar F.
  Hematology, 19(4): 213–216, Jun 2014. DOI: 10.1179/1607845413Y.0000000114
  Total Citations: 3

• Absence of Hypoalbuminemia Despite Nephrotic Proteinuria in Focal Segmental Glomerulosclerosis Secondary to Polycythemia Vera
  Ulusoy S, Ozkan G, Sonmez M, Mungan S, Kaynar K, Cansiz M, Kazaz N.
  Internal Medicine, 49(22): 2477–2480, 2010. DOI: 10.2169/internalmedicine.49.4087
  Total Citations: 4

• Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell Lung Cancer
  Kazaz SN, Oztop I.
  Turkish Thoracic Journal, 18(3): 66–71, Jul 2017. DOI: 10.5152/TurkThoracJ.2017.16042
  Total Citations: 1